Anterior thalamic syndrome

 

Ghika-Schmid F¹, Bogousslavsky J. Ann Neurol. 2000 Aug;48(2):220-7

The acute behavioral syndrome of anterior thalamic infarction: a prospective study of 12 cases.

 

Abstract

Using systematic investigations, including neurological and neuropsychological examinations and computed tomography and magnetic resonance imaging analyzed on anatomical maps, we prospectively studied 12 patients (age range, 63+/-19 years) with an isolated anterior thalamic infarct. They had acute, severe, perseverative behavior, which was apparent in thinking, speech, and all memory and executive tasks, combined with increased sensitivity to interference. They also showed superimposition of mental activities normally processed sequentially (e.g., giving biographical information while working on a calculation test), which we called palipsychism (from the Greek palin [again] and the Greek psyche [soul]). In addition, all 12 patients (8 with a left-sided infarct, 4 with a right-sided infarct) had word-finding difficulties, 7 of 12 with impaired naming, 8 of 12 with dysarthria, and 5 of 12 with hypophonia. Comprehension, repetition, written abilities, and reasoning were consistently preserved, but apathy was usual. All patients had anterograde memory impairment, with a delayed recall deficit, primarily verbal in left-sided infarcts and visuospatial in right-sided infarcts. Dysexecutive features such as difficulty in programming motor sequences were always present. Visual neglect or topographic disorientation was found in 3 patients. Magnetic resonance imaging emphasized involvement of the anterior group of thalamic nuclei, the mamillothalamic tract, and the anterior part of the internal medullary lamina, with structural sparing of the dorsomedial and ventrolateral nuclei. Sequential follow-up examinations showed spectacular improvement within a few months, with the only significant persisting abnormalities being memory dysfunction and apathy. The acute behavioral syndrome of anterior thalamic infarction is dominated by palipsychism, which corresponds to an overlap of sequential cognitive processes in two or more domains. Its association with severe perseverative behavior with increased sensitivity to interference, anterograde memory retrieval deficit, intrusions, naming difficulties with dysarthria and hypophonia, and apathy is suggestive of this type of infarct.

Malignant subtype of Parkinsons

JAMA Neurology august 2015

Importance  There is increasing evidence that Parkinson disease (PD) is heterogeneous in its clinical presentation and prognosis. Defining subtypes of PD is needed to better understand underlying mechanisms, predict disease course, and eventually design more efficient personalized management strategies.

Objectives  To identify clinical subtypes of PD, compare the prognosis and progression rate between PD phenotypes, and compare the ability to predict prognosis in our subtypes and those from previously published clustering solutions.

Design, Setting, and Participants  Prospective cohort study. The cohorts were from 2 movement disorders clinics in Montreal, Quebec, Canada (patients were enrolled during the period from 2005 to 2013). A total of 113 patients with idiopathic PD were enrolled. A comprehensive spectrum of motor and nonmotor features (motor severity, motor complications, motor subtypes, quantitative motor tests, autonomic and psychiatric manifestations, olfaction, color vision, sleep parameters, and neurocognitive testing) were assessed at baseline. After a mean follow-up time of 4.5 years, 76 patients were reassessed. In addition to reanalysis of baseline variables, a global composite outcome was created by merging standardized scores for motor symptoms, motor signs, cognitive function, and other nonmotor manifestations.

Main Outcomes and Measures  Changes in the quintiles of the global composite outcome and its components were compared between different subtypes.

Results  The best cluster solution found was based on orthostatic hypotension, mild cognitive impairment, rapid eye movement sleep behavior disorder (RBD), depression, anxiety, and Unified Parkinson's Disease Rating Scale Part II and Part III scores at baseline. Three subtypes were defined as mainly motor/slow progression, diffuse/malignant, and intermediate. Despite similar age and disease duration, patients with the diffuse/malignant phenotype were more likely to have mild cognitive impairment, orthostatic hypotension, and RBD at baseline, and at prospective follow-up, they showed a more rapid progression in cognition (odds ratio [OR], 8.7 [95% CI, 4.0-18.7]; P < .001), other nonmotor symptoms (OR, 10.0 [95% CI, 4.3-23.2]; P < .001), motor signs (OR, 4.1 [95% CI, 1.8-9.1]; P = .001), motor symptoms (OR, 2.9 [95% CI, 1.3-6.2]; P < .01), and the global composite outcome (OR, 8.0 [95% CI, 3.7-17.7]; P < .001).

Conclusions and Relevance  It is recommended to screen patients with PD for mild cognitive impairment, orthostatic hypotension, and RBD even at baseline visits. These nonmotor features identify a diffuse/malignant subgroup of patients with PD for whom the most rapid progression rate could be expected.

View Original Article

Pellagra and spinal myoclonus

 

Park K, Oeda T, Sawada H. A case of alcoholic pellegra encephalopathy presenting with spinal myoclonus.  Neurology Clinical Practice 5; 472-3.

 

The authors present a case of alcoholic pellagra  with confusion and myoclonus responding dramatically to administration of niacin1500 mg per day starting 16 days after admission.  Essential points include:

 

1. Pellagra is rare in US but not in alcoholics

2. Dermatitis may be subtle and not appreciated

3.  Thiamine and niacin levels may be normal

4.  Thiamine may cause worsening due to increased demand for niacin

5.  Myoclonus in context is important to diagnosis, often stimulus sensitive

6.  Severe sensory ataxia, incontinence and dysautonomia also occur and improve with treatment

 

the 4 D's of pellagra, again, are , diarrhea, dementia, dermatitis and death

Scurvy in neurologic disease

 

Meisal K, Daggubati S,Josephson SA. .  Scurvy in the 21st century?  Vitamin C deficiency presenting to the neurologist.  Neurol Clin Prac 2015; 5:491-493.

 

Authors present a series of cases with vitamin C deficiency and review some of the neuro manifestations and non neuro manifestations, ; the former are not widely known. 

 

Patients with deficiency were caused by various other causes,including autism, poor status without access to produce, usually rural, were not alcohol users, had measurable low vitamin C levels.  Gingival hyperplasia, rash and bleeding were non neurologic manifestations. People bruised,especially on their thighs, Some had other nutritional diseases..  Pain, achiness and weight loss are expected.

 

Neuro manifestations included positional tremor, neuralgias100 %), focal weakness (50 %)  including footdrop and scapular winging, normal MRI's, long tract signs including hyperreflexia and plantar extensors, fatigue, trouble concentrating, headache, anxiety, and imbalance.

 

Patients recovered dramatically with treatment.

Idiopathic hypertrophic pachymeningitis

 

  Dumont AS, Clark AW, Sevick RJ, Myles ST. Idiopathic hypertrophic pachymeningitis:  A report of two cases and review of the literature.

 

Background-- Authors note entity was described by Charcot and Joffroy, and that there are three forms:  spinal, intracranial and craniospinal (latter is rarer). 

 

Past cases were often attributed to specific etiologies but most recent cases are idiopathic after investigation.  Authors case 1 underwent 2 surgeries for biopsy/decompression , had persistent pain and numbness, but was non progressive for 15 years after one early relapse.  The second one received steroids after biopsy with resolution of symptoms and MRI changes.  Authors argue based on above that the condition is not autoimmune. 

 

Literature review suggested a worse prognosis for patients with "inflammatory signs" (fever, high sed rate, CRP, or elevated WBC). 

 

Associations include infections: syphilis, TB, HTLV-1, fungi; may be presenting sign of adjacent ear or sinus infection.  Autoimmune associations include RA, orbital pseudotumor, multifocal fibrosclerosis, MCTD, Wegener's granulomatosis.    The 23 reports run the gamut from marked to slight improvement to deterioration and late recurrence or surgical death. 

 

For interest, Charcot's clinical descriptors divided the spinal form into distinct stages: first intermittent radicular pain that later became continuous; then muscle weakness and atrophy; then spastic paralysis and loss of sphincter control.  Radicular signs can be confined to the upper extremities and evolve over weeks to months or even a year. 

 

The cranial form frequently presents with a headache, cranial neuropathies and ataxia. 

 

Authors emphasize the need for pathologic confirmation.

CNS metastases in breast cancer patients: prognostic implications of tumor subty

CNS metastases in breast cancer patients: prognostic implications of tumor subtype; Bachmann C, Schmidt S, Staebler A, Fehm T, Fend F, Schittenhelm J, Wallwiener D, Grischke E; Medical Oncology (Northwood; London; England) 32 (1), 400 (Jan 2015)

 

Development of brain metastases (BM) in breast cancer leads to limited survival. The therapeutical options are limited. There are less data about the risk factors and prognostic importance in BM. Objective is to investigate predictors of central nervous system metastases and outcome after diagnosis of BM according to tumor subtype. Based on medical records, 80 consecutive patients with primary non-metastatic operable breast cancer, treated at Department of Gynecology, University of Tübingen, and who developed BM during follow-up, were retrospectively analyzed. Clinicopathological parameters and their prognostic impact were evaluated. A node involvement (40 %), ER/PR negative (53.75 vs. 61.25 %), triple negative (28.75 %) and HER2+ status (40 %) were associated with BM. BM in breast cancer patients lead to a shortened survival. In cerebral metastatic breast cancer patients with HER2-negative and triple-negative, patients had significant shorter survival after detection of BM compared with HER2-positive and non-triple-negative patients (p = 0.001; p = 0.03). Risk of BM varies significantly by subtype. Understanding the biology of metastases can help categorize patients into prognostically useful categories and tailor treatment regimens for individual patients. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic BM and of treatment of triple-negative patients.

MMN and treatment responsiveness

 

Slee M, Selvan A, Donaghy M.  Neurology 2007; 69:1680-1687.

 

Authors look at 47 patients retrospectively and found that strict adherence to consensus criteria was a barrier to treatment.  Neither conduction block nor antibody status is a reliable predictor of treatment responsiveness.

 

Some of the pearls in the article:  Conduction block was present in 66%; GM1 antibody in a minority (25 %) and was not associated with conduction block. 27 % had lower limb onset, bu tin those patients, arm weakness typically developed subsequently.  Patients may have an acute or subacute onset with spontaneous resolution.  MMN can be PRECIPITATED by the use of steroids, and is usually not helped by steroids.  It "is evident from our study and others (Pakkiam AS, Perry GJ, Multifocal motor neuropathy without overt conduction block. Muscle Nerve 1998; 21: 243-245) that IVIG responsive  MMN occurs regularly without conduction block being demonstrated."  "A redefinition of conduction block which eliminates temporal dispersion as a restrictive factor and which helps predict IVIG responsiveness, (see Ghosh and Busby, JNNP 2005) categorized a further 15 % of our patients with conduction block."  "Our study suggests a decrement if IVIG responsiveness over time."  Using higher doses of 1.92 g/kg/6 weeks does better than Utrecht group of .54 g/kg /mo.  Disability self reports were more accurate than MRC scale scores with overall clinical change.

 

"Recognition of the clinical picture is the mainstay of diagnosis of MMN outside the researchg setting.  Weakness in nonwasted muscles and differential weakness across a common terminal motor nerve are the cardinal features.  Differential finger extension weakness is a frequent early manifestation likely reflecting vulnerabilities of the terminal branches of the posterior interosseous nerve." 

 

Blogger note-- this citation is extremely important for dealing with insurance companies to obtain approval for IVIG. 

 

Take away-- to take care of the patient, don't look at the test, be a doctor and a neurologist

Diploma?

Diploma?

http://tiny.cc/txntso23yf

Causes of pappilledema (bilateral) with good optic nerve function

increased intracranial pressure

 

malignant hypertension

 

toxins (amiodarone,cyclosporine)

 

sleep apnea syndrome

 

uveitis, eg. sarcoidosis

 

Abdominal auras and left sided localization of cps

Abdominal auras in patients with mesial temporal sclerosis; Kuan YC, Shih YH, Chen C, Yu HY, Yiu CH, Lin YY, Kwan SY, Yen DJ; Epilepsy & Behavior 25 (3), 386-390 (Oct 2012)To better clarify abdominal auras and their clinical correlates, we enrolled 331 temporal lobe epilepsy patients who received surgical treatment. Detailed descriptions of their auras were obtained before surgery and reconfirmed during postoperative outpatient follow-ups. Pathology revealed mesial temporal sclerosis (MTS) in 256 patients (77.3%) and 75 non-MTS. Of 214 MTS patients with auras, 78 (36.4%) reported abdominal auras (vs. 30.4% in non-MTS, p=0.439): 42 with left-sided seizure onset, and 36 with right-sided seizure onset. Moreover, 49 of the 78 MTS patients had abdominal auras accompanied by rising sensations (vs. 2 of 14 in non-MTS group, p=0.004). The"rising air"was initially described to locate to the epigastric (47.8%) or periumbilical area (45.7%) and mostly reached the chest (40.4%) or remained in the abdominal region (27.1%). An epigastric location of"rising air"favored a left-sided seizure onset, and non-epigastric areas favored right-sided seizure onset (p=0.018). Finally, we found that abdominal auras with or without rising sensations did not predict postoperative seizure outcomes.

The locus ceruleus norepinephrine system

Functional organization and potential clinical significance. Benarroch EE. Neurology 2009; 73:1699-1704

Numbered hits from article

1. NE plays a role in arousal, attention, stress response, long term synaptic plasticity, pain modulation, motor control, energy homeostasis and local blood flow. LC is implicated in sleep and arousal disorders, ADHD, PTSD. Refs 1-9 give review articles. See Annu Rev Neurosci 2005, eg.

2. Changes in LC activity anticipate changes in the behavioral state. LC firing can be tonic or phasic. Tonic activity correlates with wakefulness, decreases in SWS and is abolished in REM sleep. There is a sustained increase in tonic discharge in response to environmental stimuli that elicit behavioral arousal and exploratory behavior. During focused attention and accurate task performance, LC neurons reduce their tonic firing to a moderate rate and respond phasically to task-relevant stimuli. Phasic bursts correspond to highly accurate behavioral responses.

Lipid rafts, protein scaffold and neurologic disease

Benarroch EF. Neurology 2007; 69: 1635-1639.

Review article. Lipid rafts are specialized microdomains of the plasma membrane involved in vesicular transport and signalling mechanisms. They are encoded in cholesterol, sphingolipids, and scaffolding prteins such as caveolins and septins. Mutation of caveolin-3 is associated with diverse muscle disorders. Lipid rafts may be the site of abnormal processing of APP and prion protein.. Impaired septin-4 function can lead to synuclein accumulation and neurotoxicity in Parkinson's disease.

Lipid rafts are also characterized by their interactions with the cytoskeleton. Caveolin and flotillin act as scaffolding proteins that recruit signalling proteins into lipid rafts. Cholesterol depletion disrupts lipid rafts, leading to decreased accunulation and uptake of glutamate, GABAm or serotonin transporters. Caveolin 3 colocalizes with dysferlin. Mutations of CAV# are linked to limb girdle dystrophy 1C, rippling muscle disease, hyperCKEemia, distal myopathy, and a recessive form of LGD. Septin 4 is a component of the presynaptic scaffold in dopaminergic neurons projecting to the striatum.

Serum uric acid and brain ischemia in normal elderly adults

Schretlen DJ, Inscore AB, Vannorsdall TD et al. Neurology 2007; 69:1418-1423.

The authors make the case for uric acid in brain function/dysfunction. UA is a natural antioxidant, with concentrations tenfold those of Vitamins c and e. Low UA is found in patients with MCI AD and PD. High UA predicts better outcome after stroke in one study (see Chamorro, Stroke, 2002) and in experimental models. However high UA also predicts occurrence of stroke, second stroke, fatal MI. Allopurinol protects against stroke damage in an animal model, and high UA correlates with HTN, atherosclerosis, type 2 DM and the metabolic syndrome. Studies show elderly participants with higher UA levels were 2.7 to 5.9 times more likely to be in the lowest quartile of processing speed, verbal and working memory.

In the present study, patients with higher UA were more likely to have increased volume of WMHs on brain MRI. There was a 4-5 x increased likelihood if having excessive ischemic burden.

The authors speculate that UA can be prooxidant as well as anti-oxidant.

This blogger, a skeptic, believes that high UA is a marker for dehydration and capillary sludging and that hydrating the elderly is a good way to reduce stroke. Therefore, aside from its biologic properties, UA is just a marker for the state of hydration. These authors from jhmi (johns hopkins) did not appreciate or address this obvious clinical point.

Postscript--review article Feig DI, Kang DH, Johnson RH NEJM 2008;359:1811-1821 "Uric acid and cardiovascular risk" also reviews subject from a different vantage point. They note Framingham does not currently consider urate a risk factor. This is a nice review article with lots of good references.

GHB

Snead OC, Gibson KM. Gamma hydroxybutyric acid. NEJM 2005; 352:2721-2732.
Benarroch EE. Y-Hydroxybutyric acid and its relevance in neurology. Neurology 2009; 72: 282-286.

GHB is formed from endogenous GABA or exogenous dosing. Its effects are modulated both by GABA-B and GHB receptors. The former, within mesocorticolimbic dopamine pathways is probably responsible for the addictive nature. Effects of exogenous drug include triggering the onset of slow wave sleep (thus its use in cataplexy), intoxication, tolerance, withdrawal and addiction. It also may be used in alcohol withdrawal and intoxication. Accumulation may underlie some signs of SSADH deficiency in humans.

The sedative properties are similar to those previously seen in gamma butyrolactone 13 years ago, because that drug is metabolized to GHB. GHB occurs naturally from GABA and resembles neurotransmitters, and is released by neuronal depolarization in a calcium dependent fashion. The high affinity receptor is probably presynaptic and G protein coupled, and is located in the hippocampus, thalamus, and neocortex. GABA A receptors (not related here) result in influx of chloride ions and the generation of a fast inhibitory post-synaptic potential, whereas the GABA B receptor mediates a slow inhibitory postsynaptic potential. GABA B receptors mediate effects through voltage dependent inhibition of high voltage activated calcium channes. GHB and GABA B receptor may be one and the same (controversial). Natural GHB is present in micromolar quantities, can activate GHB receptors but not GABA B receptors. Exogenous GHB probably acts through GABA B receptor. GHB conversion to GABA (normal metabolism) can be inhibited by valproic acid and ethosiximide.

GHB has a half life of 20-30 minutes, peak levels occur at 40 minutes, and it can be detected in urine for 12 hours. The narrow margin of safety is such that doses up to 20-30 mg/kg lead to euphoria and memory loss, drowsiness and sleep. Twice this dose leads to coma.

The clinical hallmark is rapid onset of profound coma, myoclonus, respiratory depression, hypoventilation, and bradycardia. Hupothermia, vomiting, mydriasis, or miosis also may occur. The signs persist for a short time. The rapid/uneventful recovery creates a false sense of security in users. The level of consciousness does not correlate with the serum level of GHB. It should be considered in any young man with rapid onset of coma when head trauma, metabolic disorders, CNS infection and increased intracranial pressure are excluded. It can be considered in women as well (date rape drug).

Death due to overdose can occur to respiratory compromise, aspiration, positional asphyxia, pulmonary edema, accidental trauma, or injury. Over half of abusers also use other drugs, and alcohol is synergistic in causing respiratory depression and hypotension.

Management is supportive (airway, breathing, circulation) oxygen, and atropine for persistent bradycardia. Mucosal burns can occur as illicit forms are synthesized from gamma butyrolactone and sodium hydroxide. There are no specific antidotes. Charcoal is not indicated due to short half life and risk of aspiration. Physostigmine is not indicated.

GHB and its prodrugs (gammabutyrolactone and 1,4 butanediol) are abused by bodybuilders because they were thought to stimulate the production of growth hormone. The diol prodrug is metabolized by an alchohol dehyrogenase, and is made more toxic by alcohol, possibly because of competition by two drugs for that enzyme. GHB is available by schedule one prescription. Names for illicit forms include G, liquid ecstasy, grievous bodily harm, Georgia home boy, liquid X, soap, easy lay, salty water, scoop, cherry meth, and nitro. The two prodrugs are available on internet for sale, advertised for mood enhancement, sleep induction and bodybuilding (GBL, gamma butyrolactone).

The psychic effects include reduced anxiety, euphoria, enhanced sensuality, and emotional warmth. It is common at raves. Raves are all night dance parties attended by large number sof young people with clandestine venues, hynotic music and liberal use of drugs including GHB. Circuit parties differ in that they are usually attended by homosexual/bisexual men. This is a problem, because protease inhibitors, given for HIV infection, alter the metabolism of GHB through interaction on P-450 system. Even small doses can cause coma.

Rebound insomnia after 2-3 hours of sleep can lead to repeat dosing with an additive response. Chronic users may thus take doses every 2-4 hours around the clock, and suffer withdrawal when they stop taking it with symptoms similar to those of benzodiazepine or alcohol. Once daily GHB users (for narcolepsy) do not develop withdrawal. The minimum dose for withdrawal is 18 g (10g for precursor) but doses are variable. Symptoms are mild at onset and include tremor, tachycardia, restlessness, insomnia, anxiety, or vomiting and can build up, later causing delirium, frank psychosis, diaphoresis or death. Withdrawal can last weeks or even months and patients may abuse benzodiazepines or alcohol to self-medicate symptoms. Lorazepan or diazepam often in very high doses may be needed to treat withdrawal. Antipsychotics and antiepileptic drugs are not needed. Baclofen could be considered a potential drug for weaning as it is a GABA B receptor agonist and helps in other addictive drugs by decreasing reinforcement effects in dopaminergic mesocorticolimbic pathways,

Sexual assault (date rape drug) occurs with doses of 10-20 mg/kg, as drug causes increased libido, anterograde amnesia, suggestibility and passivity. In suspected patients, early collection of blood and urine is important for detection. It is not readily measurable and may need to be sent out to a state reference lab.

Potential legitimate uses include narcolepsy, alcohol dependence and withdrawal, stimulus induced paroxysmal drop attacks in Coffin-Lowry syndrome, tardive dyskinesia and bipolar affective disorder.

See discussion of metabolic disease SSADH (related) here :
http://www.blogger.com/post-edit.g?blogID=30837446&postID=3676676890024591264


Letters to editor were published in NEJM 2005; 353: 1632-33. One writer opined that rapid diagnosis through tox screens should be detectable by urinary organic acid analysis, similar to the way succinic dehydrogenase deficiency is diagnoses. Another writer opined that GHB is approved for alcohol detoxification in Europe, as well as maintenance of long term abstinence. No abuse occurs with greater fractioning of the dose. A third writer stresses the importance of assessing agitation as a sign of co-intoxicants. They plan to publish a series on 146 deaths with GHB, including 138 CP deaths, 4 drownings, 3 MVA fatalities, and 1 death to a fire while intoxicated.

Tale about Tau

Ashe KH. A Tale about tau. NEJM 2007;357:933-935.

The author reviews evidence suggesting that tau is an appropriate drug target for Alzheimer's disease. They cite a mouse model by Roberson ED et al (Science 2007;316:750-754)that expresses amyloid precursor protein encoded by two genes carrying two mutations for early onset familial AD. APP cleaves to form A Beta , the main component of amyloid plaques of AD, and the mice develop abnormal behaviors, memory loss and plaques. In these mice, depleting endogenous tau (from NFT's) (by crossing with mice in whom the tau gene was inactivated) , that did not result in decreased amyloid plaques in the mice, but did result in prevention of behavioral disturbance, memory loss and sudden death. Improvement occurred even with a 50 % reduction of tau. Soluble a Beta assemblies cause memory loss and bind to dendritic spines, the postsynaptic elements that house the key elements of memory formation. NFT's are not as important, as mice with neuritic plaques and tangles with reduced tau had normal behavior.

Tau joins other molecules that mediate the effects of aBeta on memory and synaptic plasticity. Tau lives in axons where it binds microtubules to polymerize and stabilize molecules. Under pathologic conditions, tau interacts with cytoskeletal component actin, mediating changes in dendritic spines and synaptic plasticity. Dendritic spines also are entry points for excitotoxicity.

Mice with low tau were resistant to excitotoxic seizures, suggesting it might potentiate excitotoxic effects of a Beta. Since tau facilitates brain dysfunction due to A Beta and excitotoxin, and even a partial low level can diminish bad effects, "propels tau to a higher spot" on list of therapeutic targets for Alzheimer's disease, and stroke and epilepsy (that involve excitotoxicity). Author cautions that TIMING of tau reduction may be important, as it may be important in development rather than in adult specimens.

Rebooting the immune system with cytoxan

Drachman et al. Annals of Neurology2003 and Lewis and Lisak editorial same issue.

Drachman et al. take advantage of the resistance of stem cells to cycophosphamide because they lack the enzyme aldehyde dehydrogenase. That makes bone marrow transplantation unneeded, with the hope that the rebooted marrow lacks the pathologic autoimmune response seen before treatment. It is not clear that rebooting is not simply effective because it is prolonged severe immunosuppression. In other AI disorders, the technique has been used producing remissions but also deaths.

Do Bone Marrow Cells Generate Neurons?

Hess DC et al. Arch Neurol 2004;61:483-485. Neurological Review.

Bone marrow cells can evolve into hepatocytes, endothelial, muscle, cardiac muscle or neuronal cells, in vitro and in vivo. Method used is transplanting genetically marked bone marrow in mice that have received lethal radiation. The "radiation chimera" is often a sex mismatch, eg. a y chromosome in a female. Many neurologic structures received marked cells including cells expressing GFP and NS proteins, in olfactory bulb, cortex, hypothalamus, hippocampus, amygdala, PAG, striatum, Purkinje cells of cerebellum but not spinal cord or brainstem. This also has been shown in several humans who received transgender bone marrow transplants . Some evidence suggests this is due to cell fusion. It is not yet clear whether these cells express normal function.

Apoptosis and Caspaces in neurodegenerative diseases

Friedlander RM. Mechanisms of disease. NEJM 2003; 348:1365-1375.

Caspaces (cysteine dependent, apartate specific proteases) are the executioners in the apoptotic programs for cell death. This work was originated in nematodes and has become prominent in the past fifteen years only. There are upstream or initiator caspaces and downstream executioner caspaces. Cytochrome c, a part of the electron transport chain, is intimately involved . There also are inhibitors of caspaces to prevent apoptosis gone amuk.

In acute neurologic diseases, necrotic death and apoptosis both occur. In neurodegenerative diseases, apoptosis predominates. Caspaces may be important in AD, PD, HIV related dementia. In addition, a role exists in ALS mice, in which caspace 1 and 3 are upregulated. 10 % of patients have a SOD mutation and in these it may be preordinant. In Huntington's disease, huntingten is depleted which is a substrate for caspace 1. Increased caspace mediated cleavage of huntingten leads to hgih levels of huntingten fragments and depleted wild type huntingten. Down regulation of receptors also occurs, and this is caspace dependent but not considered apoptosis.

Minocycline inhibits nitric oxide and reduces the severity of ischemia induced tissue injury. It also inhibits caspace. Neuroprotection with it has been observed in models of HD, ALS, brain injury, PD and MS. The mechanism is the direct inhibition of the release of cytochrome c, and inhibition of downstream activation of caspace 3. It is orally bioavailable, crosses the bloodbrain barrier is safe, and is being tested in HD and ALS.

Apoptosis is "contagious" as it occurs, as it releases pro-apoptotic factors causing neighborhood to all commit apoptosis It is therefore a reasonable idea for treatment of acute neurologic disease as well.

Neuroprotection in the peripheral nervous system

Hoke A. Neuroprtoection in the peripheral nervous system. Arch Neurol 2006; 63: 1681-1685

The authors criticise the dogma holding that there is a "dying back " neuropathy in which the axon degrades centripetally from the end. In other work (Griffin and Hoke) the concept of last field of irrigation is reversed, and neuronal body depends upon target derived growth factors for survival. Also, Raff et al proposed that the so-called dying back neuropathy is a programmed responsed similar to apoptosis. Neuroprotective activities designed for neuronal survival, such as in the brain or spinal cord, may be inappropos due to lack of significant neuronal death in many peripheral neuropathies. The author proposes research center on 2 areas: mechanisms involving distal axonal degeneration, and axon-glia mechanisms important for neuroprotection.

Unlike Wallerian degeneration, in many peripheral neuropathies there is compartmental degeneration of axons without physical compartmentalization. In HIV virus envelope gp120 involves chemokine receptors on Schwann cells. In familial ALS, mutations in the SOD 1 gene suggested initial ep abnormality was explained by axonal degeneration not neuronal loss.

In stroke literature ischemic preconditioning protects neurons and limits damage from future events. This endogenous protection may be related to astrocyte secreted erythropoietin. In sciatic transection in rats, Schwann cells in contact upregulate erythropoetin expression and DRG ensory neurons upregulate receptors for the same. The injury signal in nitric oxide, that activates hypoxia-inducible-factor 1 that induces erythropoetin changes. Exogenous erythropoietin helps in models of neuropathy due to paclitaxel, diabetic neuropathy, and cisplatinum induced PN.

The authors also note a mouse strain that is resistant to degeneration after injury, due to a Wlds gene (Wallerian degeneration-slow). Further studies of axon-glia interactions are needed.